The agreement provides Biological E (BE) with an option for novel production technologies for both heparin- and chondroitin-related carbohydrate compounds. Heparinex and Choncept are funded and managed by life sciences venture firm Emergent Technologies (ETI).
Bill Strieber, vice president, new business development for ETI and managing director of both Heparinex and Choncept, said: “The agreement with BE gives us additional validation of the broad utilization platform of our proprietary carbohydrate production technologies. It also provides industrial scale-up capabilities and the international marketing infrastructure to allow for substantial increase in business opportunities.”